Tuberculosis research and development: seeding the future.

Christian Lienhardt, Alimuddin Zumla, Nebiat Gebreselassie, Mike Frick, Glenda Gray, Tereza Kasaeva, Mario Raviglione

Abstract readComment

In one paragraph

Article in The Lancet. Respiratory medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

Comparing timelines and evidence available to support new TB, HIV, and HCV drug approvals: The same, only different.PloS one · 2022
Trial
The United Nations' ambitious roadmap against tuberculosis: opportunities, challenges and the imperative of equity.Future science OA · 2024
Article
Reevaluating progression and pathways followingProceedings of the National Academy of Sciences of the United States of America · 2023
Article
New perspectives on an ancient pathogen: thoughts for World Tuberculosis Day 2022.Microbiology (Reading, England) · 2022
Article
High sensitivity of ultrasound for the diagnosis of tuberculosis in adults in South Africa: A proof-of-concept study.PLOS global public health · 2022
Article
Exploring local realities: Perceptions and experiences of healthcare workers on the management and control of drug-resistant tuberculosis in Addis Ababa, Ethiopia.PloS one · 2019
Article

4 · The record

Corrections and comments

Comment on
The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era.2018

5 · Who and what money

Authors and funding

7 authors.

Christian LienhardtGlobal TB Programme, WHO, Geneva 1211, Switzerland. Electronic address: lienhardtc@who.int.

Alimuddin ZumlaCentre for Clinical Microbiology, Division of Infection and Immunity, University College London, London, UK; NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, UK.

Nebiat GebreselassieGlobal TB Programme, WHO, Geneva 1211, Switzerland.

Mike FrickTreatment Action Group, New York, NY, USA.

Glenda GrayMedical Research Council South Africa, Cape Town, South Africa.

Tereza KasaevaGlobal TB Programme, WHO, Geneva 1211, Switzerland.

Mario RaviglionePrévessin-Moëns, France.

Funding

World Health Organization 001

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ForecastingTuberculosisHumansResearch

Identifiers

PMID29595503

DOI10.1016/S2213-2600(18)30050-X

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.